Subscribe
8 December 2017Americas

Non-profit group continues battle against Gilead patents

Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More on this story

Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Americas
Public interest group challenges ‘unmerited’ Gilead patents
26 October 2017   Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

More features

Sanofi unit loses genetic disorder patent at EPO after trio of challenges
INTA confirms London as host city for Annual Meeting 2026
INTA unveils key principles on AI and IP rights at Annual Meeting
Illumina takes aim at rival in gene sequencing spat
Novartis tops Big Pharma in global trademark portfolios
PierFerd hires partner with medtech expertise
NanoString to pay 10x Genomics $68m in global settlement
Federal Circuit revives CRISPR feud citing PTAB errors